ISHAS Professional & Academic Forum on Targeting Hyaluronan/Hyaluronic Acid (HA) in COVID-19 Infection and Pathology. (You do not need to be a Member of ISHAS to post on this forum.)
  1. Anna Plaas
  2. Therapeutics Targeting Hyaluronan after COVID-19 Infection
  3. Wednesday, 06 May 2020
Modulation of bleomycin-induced lung fibrosis by pegylated hyaluronidase and dopamine receptor antagonist in mice.
Skurikhin EG, Pershina OV, Reztsova AM, Ermakova NN, Khmelevskaya ES, Krupin VA, Stepanova IE, Artamonov AV, Bekarev AA, Madonov PG, Dygai AM.
PLoS One. 2015 Apr 30;10(4):e0125065. doi: 10.1371/journal.pone.0125065. eCollection 2015.
PMID: 25927611

Treatment with chondroitinase ABC alleviates bleomycin-induced pulmonary fibrosis.
Kai Y, Yoneyama H, Koyama J, Hamada K, Kimura H, Matsushima K.
Med Mol Morphol. 2007 Sep;40(3):128-40. doi: 10.1007/s00795-007-0370-y. Epub 2007 Sep 18.
PMID: 17874045
There are no comments made yet.
Anthony Day
Forum Moderator
Accepted Answer Pending Moderation
Hi Anna,
Thanks for posting these publications.
What do you think these papers are telling us about the potential to use hyaluronidase and chondroitinase for the lung pathology associated with COVID-19?
There are no comments made yet.
  • Page :
  • 1

There are no replies made for this post yet.
Be one of the first to reply to this post!